Molecule
Molecule
molucle img

Chemistry at the Core

We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.

An elderly couple enjoying a peaceful day on the beach. An elderly couple enjoying a peaceful day on the beach. An elderly couple enjoying a peaceful day on the beach.
molucle img

Built for Patients

We partner with physician-scientists to identify patient needs and the limitations of existing therapies.

Driven by Purpose

We are passionate about using our expertise to address the needs of patients with cancer.

Nathan McConarty

Nathan McConarty, JD

Legal
Baudouin Gerard

Baudouin Gerard, PhD

Medicinal Chemistry
Tina Kehrig

Tina Kehrig

Clinical Operations
Benjamin Lane

Benjamin Lane, PhD

Technical Operations
Anupong Tangpeerachaikul

Anupong Tangpeerachaikul, PhD

Biology
Tuan Minh Nguyen

Tuan Minh Nguyen, PhD

Biology
Kari Andrews

Kari Andrews

Clinical Operations
Christian Martin

Christian Martin

Translational Development
John Soglia

John Soglia, PhD

Translational Development
Mikhaila Ruth

Mikhaila Ruth

Human Resources
Deb Miller

Deb Miller, PhD, JD

Chief Legal Officer
Ashlin Miller

Ashlin Miller

Program Managements
Shashank Kulkarni

Shashank Kulkarni, PhD

Medicinal Chemistry
Matthew Metivier

Matthew Metivier

Human Resources
Greg Smith

Greg Smith

Regulatory
Gosia Riley

Gosia Riley

Clinical Operations
Amy Rochford

Amy Rochford

Clinical Operations
Lister-Chelcie

Chelcie Lister

Corporate Development
Viola Zhu

Viola Zhu, MD, PhD

Clinical Development
Kevin Staffin

Kevin Staffin

Quality Assurance
James Porter

James Porter, PhD

Chief Executive Officer
Ruth Adams

Ruth Adams

Clinical Operations
Scot Mente

Scot Mente, PhD

Computational Chemistry
Yuting Sun

Yuting Sun, PhD

Biology
Shannon Dauksis

Shannon Dauksis, PharmD

Program Management
Jason Kropp

Jason Kropp

Pharmaceutical Development
Maureen Secord

Maureen Secord

Clinical Supply Chain
Joshua Horan

Joshua Horan, PhD

Chemistry
Kristin Andrews

Kristin Andrews, PhD

Computational Chemistry
Morgan Maiola

Morgan Maiola

Quality Assurance
DeLaRosa-Rachel

Rachel DeLaRosa

Clinical Operations
Jose Rios Lizarraga

José Lizarraga

Formulation Sciences
Allison Magnan

Allison Magnan

GCP Quality Assurance
Sibao Chen

Sibao Chen, PhD

Pharmaceutical Development
Christopher Cooper

Christopher Cooper, PhD

Pharmaceutical Development
Ray Kemper

Ray Kemper, PhD

Toxicology
Virginia Vetter

Virginia Vetter

Regulatory Affairs
Alex Balcom

Alex Balcom

Chief Financial Officer
Christopher Turner

Christopher Turner, MD

Chief Medical Officer
Jeffrey Lee

Jeffrey Lee

Information Technologies
Jenn Fairbanks

Jenn Fairbanks

Clinical Operations
Jesus Garza

Jesus Garza

Financial Planning & Analysis
Stephen McNamara

Stephen McNamara

Finance
Kristi Byrnes

Kristi Byrnes

Quality Assurance
Lidya Le

Lidya Le

Clinical Operations
Darlene Noci

Darlene Noci, ALM

Chief Development Officer
Fareya Zubair

Fareya Zubair

Regulatory Affairs
Matthew Campbell

Matthew Campbell

Pharmaceutical Development
Brenda Vienneau

Brenda Vienneau, CPA, CMA

Finance
Henry Pelish

Henry Pelish, PhD

Drug Discovery
Wenzhe Fan

Wenzhe Fan

Analytical Sciences
Crespo-Jessica

Jess Crespo, CPA

Finance
Sowjanya Mangipudi

Sowjanya Mangipudi

Clinical Operations
Philip Engel

Philip Engel

Cybersecurity & Compliance
Paula Chubet

Paula Chubet

Legal
Joshua Lance

Joshua Lance, JD

Legal
Jessie Lin

Jessie Lin

Corporate Strategy & Portfolio Management

Our clinical trials

Learn More
Read the latest news

Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors

Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones